Evidence map›Paper›PMID 39912809›Full record

ArticleJournal of managed care & specialty pharmacy2025

Prevalence of obesity-related multimorbidity and its health care costs among adults in the United States.

Kyrian Ezendu, Gerhardt Pohl, Clare J Lee, Hui Wang, Xiaohong Li, Julia P Dunn

Abstract read
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kyrian EzenduEli Lilly and Company, Indianapolis, IN.
Gerhardt PohlEli Lilly and Company, Indianapolis, IN.
Clare J LeeEli Lilly and Company, Indianapolis, IN.
Hui WangTechData Service Company LLC, King of Prussia, PA.
Xiaohong LiEli Lilly and Company, Indianapolis, IN.
Julia P DunnEli Lilly and Company, Indianapolis, IN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOverweight and obesity are associated with many obesity-related complications (ORCs) and drive increased health care costs. However, data on the impact of obesity severity on multimorbidity and the effect of multimorbidity on cost and health care resource utilization (HCRU) in people with overweight or obesity are limited.

objectiveTo determine in reference to obesity-related multimorbidity (1) if prevalence increases with higher levels of weight class, (2) if higher levels of weight class are associated with an increased risk of multimorbidity at an earlier age, and (3) how HCRU and health care costs are impacted, including if there is a beyond-additive effect on ORC-related costs.

methodsThis retrospective cross-sectional study used linked electronic health records (EHRs) and insurance claims from Optum's de-identified Market Clarity Data. Costs were considered from January 1 to December 31, 2019. Patients continuously insured in 2018 and 2019 with at least 1 recorded body mass index (BMI) in 2019 were included. The presence of 17 prespecified ORCs was determined from the database based on the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. ORC-related medical services costs were based on ICD-10-CM diagnosis codes in the primary position; pharmacy costs were based on National Drug Codes. Total health care costs were the sum of medical services and pharmacy costs. Weight classes were derived from the patients' median BMI in the EHR in 2019.

resultsThe prevalence of multimorbidity increased with increasing weight levels (12.3% in overweight and 33.4% in class 3 obesity for ages 19-40 years; 41.5% and 66.6% for ages 41-65 years; and 70.6%-85.9% for age ≥65 years). Ages for predicted 50% risk of having at least 2 ORCs were 59, 54, 49, and 43 years among patients with overweight and obesity classes 1, 2, and 3, respectively. The mean effect of multimorbidity on ORC-related costs was beyond additive in those with obesity, such that the ORC-related costs were about $1,082 (151%), $1,696 (218%), and $2,433 (264%) for class 1, class 2, and class 3 obesity, respectively. This effect was not present for overweight, for which the cost was $310 (42%). Individuals with multimorbidity had higher odds of emergency department visits (odds ratio [OR] = 1.74; 95% CI = 1.73-1.76) and inpatient hospitalization (OR = 3.32; 95% CI = 3.27-3.38).

conclusionsThe prevalence of obesity-related multimorbidity increased with increasing weight classes within age groups. Obesity-related multimorbidity presented at an earlier age with higher weight class, such that the predicted probability of having obesity-related multimorbidity was more than a decade younger in class 2 and class 3 obesity compared with overweight. It was associated with increased HCRU and higher-than-expected costs exceeding the sum for the ORCs. Early diagnosis and treatment of obesity may be needed to prevent or delay the onset of obesity-related multimorbidity and limit its associated health care costs.

Indexed as

Health Care CostsMultimorbidityObesityAdultAgedBody Mass IndexCross-Sectional StudiesElectronic Health RecordsFemaleHumansMaleMiddle AgedPrevalenceRetrospective StudiesUnited StatesYoung Adult

Identifiers

PMID39912809
PMCPMC11852798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.